# To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250 mg/5 ml Oral Suspension Fed Conditions

> **NCT00883883** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)
- **DRUG:** Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)

## Key facts

- **NCT ID:** NCT00883883
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2005-05
- **Final completion:** 2005-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00883883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00883883, "To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250 mg/5 ml Oral Suspension Fed Conditions". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00883883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*